Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor–Resistant Cutaneous Melanomas

Jinhua Wang; Sharon K. Huang; Diego M. Marzese; Sandy Hsu; Neal P. Kawas; Kelly K. Chong; Georgina V. Long; Alexander M. Menzies; Richard A Scolyer; Sivan Izraely; Orit Sagi‐Assif; Isaac P. Witz; Dave S.�B. Hoon

doi:10.1038/jid.2014.418

Related publications

Article2017

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing

Gulietta M. Pupo, Suzanah C. Boyd, Carina Fung, Matteo S. Carlino, Alexander M. Menzies, Bernadette Pedersen, Peter A. Johansson, Nicholas K. Hayward, Richard Kefford, Richard A Scolyer, Georgina V. Long, Helen Rizos

Article2013

Melanomas of unknown primary have a mutation profile consistent with cutaneous sun‐exposed melanoma

Ken Dutton‐Regester, Hojabr Kakavand, Lauren G. Aoude, Mitchell Stark, Michael G. Gartside, Peter A. Johansson, Linda O’Connor, Cathy Lanagan, Varsha Tembe, Gulietta M. Pupo, Lauren E. Haydu, Christopher Schmidt, Graham J. Mann, John F. Thompson, Richard A Scolyer, Nicholas K. Hayward

Article2015

Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy

Rachael Anforth, Alexander M. Menzies, Karen Byth, Giuliana Carlos, Shaun Chou, Raghwa Sharma, Richard A Scolyer, Richard Kefford, Georgina V. Long, Pablo Fernández‐Peñas

Article2012

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma

Rachael Anforth, Tatiana Cristina Moraes Pinto Blumetti, Richard Kefford, R. Sharma, Richard A Scolyer, Steven Kossard, Georgina V. Long, Pablo Fernández‐Peñas

Article2013

38. Intralesional molecular heterogeneity in a BRAF-mutant BRAF inhibitor resistant melanoma: a case illustrating the challenges for personalised medicine

James S. Wilmott, Varsha Tembe, Julie R. Howle, Raghwa Sharma, John F. Thompson, Helen Rizos, Richard Kefford, Richard A Scolyer, Georgina V. Long